B
Beverly Alston
Researcher at National Institutes of Health
Publications - 22
Citations - 2970
Beverly Alston is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Pravastatin & Acquired immunodeficiency syndrome (AIDS). The author has an hindex of 16, co-authored 21 publications receiving 2924 citations.
Papers
More filters
Journal ArticleDOI
Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons.
Raymond T. Chung,Janet Andersen,Paul A. Volberding,Gregory K. Robbins,Tun Liu,Kenneth E. Sherman,Marion G. Peters,Margaret James Koziel,Atul K. Bhan,Beverly Alston,Dodi Colquhoun,Tom Nevin,George Harb,Charles van der Horst +13 more
TL;DR: The marked discrepancy in the rates of sustained virologic response between HCV genotypes indicates that strategies are needed to improve the outcome in persons infected withHCV genotype 1.
Journal ArticleDOI
Guidelines for preventing opportunistic infections among HIV-infected persons - 2002
Henry Masur,Jonathan E. Kaplan,King K. Holmes,Beverly Alston,Miriam J. Alter,Neil M. Ampel,Jean Anderson,A. Cornelius Baker,David A Barr,John G. Bartlett,John E. Bennett,Constance A. Benson,William A. Bower,Samuel A. Bozzette,John T. Brooks,Victoria A. Cargill,Kenneth G. Castro,Richard E. Chaisson,David A. Cooper,Clyde S. Crumpacker,Judith S. Currier,Kevin M. DeCock,Lawrence Deyton,Scott F. Dowell,W. Lawrence Drew,William Duncan,Mark S. Dworkin,Clare A. Dykewicz,Robert W Eisinger,Tedd Ellerbrock,Wafaa El-Sadr,Judith Feinberg,Kenneth A. Freedberg,Keiji Fukuda,Hansjakob Furrer,Jose M. Gatell,John W. Gnann,Mark J. Goldberger,Sue Goldie,Eric P. Goosby,Fred M. Gordin,Peter A. Gross,Rana Hajjeh,Richard Hafner,Diane Havlir,S D Holmberg,David R. Holtgrave,Thomas M. Hooton,Douglas A. Jabs,Mark A. Jacobson,Harold Jaffe,Edward N. Janoff,Jeffrey M. Jones,Dennis D. Juranek,Mari M. Kitahata,Joseph A. Kovacs,Catherine Leport,Myron J. Levin,Juan C. Lopez,Jens D Lundgren,Michael Marco,Eric Mast,Douglas L. Mayers,Lynne M. Mofenson,Julio Montaner,Richard A. Moore,Thomas Navin,James D. Neaton,Charles Nelson,Joseph F. O'Neill,Joel Palefsky,Alice Pau,Phil Pellett,John P. Phair,Steve Piscitelli,Michael A. Polis,Thomas C. Quinn,William C. Reeves,Peter Reiss,David Rimland,Anne Schuchat,Cynthia L. Sears,Leonard B. Seeff,Kent A. Sepkowitz,Kenneth E. Sherman,Thomas G. Slama,Elaine M. Sloand,Stephen A. Spector,John A. Stewart,David L. Thomas,Timothy M. Uyeki,Russell Van Dyke,M. Elsa Villarino,Anna Wald,D. Heather Watts,L. Joseph Wheat,Paige L. Williams,Thomas C. Wright +97 more
TL;DR: This fourth edition of the guidelines for preventing opportunistic infections (OIs) among persons infected with human immunodeficiency virus (HIV) is intended for clinicians and other health-care providers who care for HIV-infected persons.
Journal ArticleDOI
Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047.
Carl J. Fichtenbaum,John G. Gerber,Susan L. Rosenkranz,Yoninah Segal,Judith A. Aberg,Terrence F. Blaschke,Beverly Alston,Fang Fang,Bradley W. Kosel,Francesca T. Aweeka +9 more
TL;DR: SimVastatin should be avoided and atorvastatin may be used with caution in persons taking RTV and SQVsgc, and pravastatin does not alter the NFV pharmacokinetics, and thus appears to be safe for concomitant use.
Journal Article
1999 USPHS/IDSA Guidelines for the Prevention of Opportunistic Infections in Persons Infected with Human Immunodeficiency Virus
Henry Masur,Jonathan E. Kaplan,King K. Holmes,Beverly Alston,Neil M. Ampel,Jean Anderson,A. Cornelius,David A Barr,John Bartlett,John E. Bennett,Sam Bozzette,Richard E. Chaisson,Judith S. Currier,Lawrence Deyton,Lawrence W. Drew,William Duncan,Robert P. Eisinger,Kenneth A. Freedberg,Hansjakob Furrer,Mark J. Goldberger,Sue J. Goldie,Eric P. Goosby,Richard Hafner,Diane V. Havlir,Douglas A. Jabs,Mark A. Jacobson,Mari M. Kitahata,Joseph A. Kovacs,Catherine Leport,Claude Bernard,Juan C. Lopez +30 more
TL;DR: In August 1999, agencies of the U.S. Public Health Service (USPHS), in collaboration with the Infectious Diseases Society of American (IDSA), published 1999 Guidelines for the Prevention of Opportunistic Infections in Persons Infected with Human Immunodeficiency Virus (HIV).
Journal ArticleDOI
Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study.
John G. Gerber,Susan L. Rosenkranz,Carl J. Fichtenbaum,José M. Vega,Amy Yang,Beverly Alston,Susan W Brobst,Yoninah Segal,Judith A. Aberg +8 more
TL;DR: EFV, when administered with SIM, ATR, or PRA, can result in significant induction of statin metabolism, and the reduced inhibition of HMG-CoA reductase activity during coadministration of EFV may result in diminished antilipid efficacy at usual doses of SIM,ATR, and PRA.